Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

  • Barrios Barrera, Clara
  • Otero, Sol
  • Rodríguez García, Eva
  • Pedro-Botet, Juan
  • Pascual Santos, Julio
  • Menni, Cristina
Using targeted NMR spectroscopy of 227 fasting serum metabolic traits, we searched for novel metabolic signatures of renal function in 926 type 2 diabetics (T2D) and 4838 non-diabetic individuals from four independent cohorts. We furthermore investigated longitudinal changes of metabolic measures and renal function and associations with other T2D microvascular complications. 142 traits correlated with glomerular filtration rate (eGFR) after adjusting for confounders and multiple testing: 59 in diabetics, 109 in non-diabetics with 26 overlapping. The amino acids glycine and phenylalanine and the energy metabolites citrate and glycerol were negatively associated with eGFR in all the cohorts, while alanine, valine and pyruvate depicted opposite association in diabetics (positive) and non-diabetics (negative). Moreover, in all cohorts, the triglyceride content of different lipoprotein subclasses showed a negative association with eGFR, while cholesterol, cholesterol esters (CE), and phospholipids in HDL were associated with better renal function. In contrast, phospholipids and CEs in LDL showed positive associations with eGFR only in T2D, while phospholipid content in HDL was positively associated with eGFR both cross-sectionally and longitudinally only in non-diabetics. In conclusion, we provide a wide list of kidney function-associated metabolic traits and identified novel metabolic differences between diabetic and non-diabetic kidney disease., TwinsUK was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007–2013). The study also receives support from the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. TS is holder of an ERC Advanced Principal Investigator award. CB and the Genodiab-Mar cohort is supported by a grant from the Institute Carlos III (FIS-FEDER PI16/00620) and RedinRen RD16/0013/0009. CM is funded by the MRC AimHy (MR/M016560/1) project grant. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research has been supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The research leading to these results has received funding from the European Union Seventh Framework Programme under grant agreement [n°313010] (Large-scale prospective cohort studies - BBMRI-LPC; www.bbmri-lpc.org), [n°305280] (Methods for Integrated analysis of multiple Omics datasets – MIMOmics; http://www.mimomics.eu/) and under grant agreements [n°603288] (Systems Biology to Identify Molecular Targets for Vascular Disease Treatment – SysVasc; http://www.sysvasc.eu/). The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation of Finnish Diabetes Association. MAK was supported by the Sigrid Juselius Foundation, Finland. MAK works in a Unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_12013/1). PW is funded by the Academy of Finland (312476 & 312477), and the Novo Nordisk Foundation Competing Interests.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like features

  • Lim, Albert Z.
  • McMacken, Grace M.
  • Rastelli, Francesca
  • Oláhová, Monika
  • Baty, Karen
  • Hopton, Sila
  • Falkous, Gavin
  • Töpf, Ana
  • Lochmüller, Hanns
  • Marini-Bettolo, Chiara
  • McFarland, Robert
  • Taylor, Robert W.
Mitochondrial DNA (mtDNA)-related diseases often pose a diagnostic challenge and require rigorous clinical and laboratory investigation. Pathogenic variants in the mitochondrial tRNA gene MT-TY, which encodes the tRNATyr, are a rare cause of mitochondrial disease. Here we describe a novel m.5860delTA anticodon variant in the MT-TY gene in a patient who initially presented with features akin to a childhood onset myasthenic syndrome. Using histochemical, immunohistochemical and protein studies we demonstrate that this mutation leads to severe biochemical defects of mitochondrial translation, which is reflected in the early onset and progressive phenotype. This case highlights the clinical overlap between mtDNA-related diseases and other neuromuscular disorders, and demonstrates the potential pitfalls in analysis of next generation sequencing results, given whole exome sequencing of a blood DNA sample failed to make a genetics diagnosis. Muscle biopsy remains an important requirement in the diagnosis of mitochondrial disease and in establishing the pathogenicity of novel mtDNA variants., AL, RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z); RM and RWT also receive support from the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK) (G0800674), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council L016354), UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS Specialist Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (http://www.newcastle-mitochondria.com/). GM is supported by the Association of British Neurologists Clinical Research Training Fellowship. Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data were analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum

  • Urreizti, Roser
  • López Martín, Estrella
  • Martínez Monseny, Antonio Federico
  • Pujadas, Montserrat
  • Castilla-Vallmanya, Laura
  • Pérez Jurado, Luis Alberto
  • Serrano, Mercedes
  • Natera de Benito, Daniel
  • Martínez Delgado, Beatriz
  • Posada de la Paz, Manuel
  • Alonso, Javier
  • Marín Reina, Purificación
  • O'Callaghan, Mar
  • Grinberg, Daniel
  • Bermejo Sánchez, Eva
  • Balcells, Susana
Background: Pathogenic variants of the lysine acetyltransferase 6A or KAT6A gene are associated with a newly identified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity and speech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initially reported as causing this disorder, missense mutations, to date always involving serine residues, have recently been associated with a form of the disorder without cardiac involvement. Results: In this study we present five new patients, four with truncating mutations and one with a missense change and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], also predicted to affect splicing by in silico tools, was functionally tested in the patient’s lymphocyte RNA revealing a splicing effect for this allele that would lead to a frameshift and premature truncation. Conclusions: An extensive revision of the clinical features of these five patients revealed high concordance with the 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, a high bulbous nose, and recurrent infections. Other features present in some of these five patients, such as cryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome., Funding was from Associació Síndrome Opitz C, Terrassa, Spain; Spanish Ministerio de Economía y Competitividad (SAF2016–75948-R) and from CIBERER (U720). SpainUDP is an initiative funded by the Instituto de Salud Carlos III. Also, the whole exome sequencing of patient 3 was funded through 2016 BBMRI-LPC Call (FP7/2007–2013, grant agreement n° 313010) and patient 5 was sequenced thanks to the PERIS·URDCat program, funded by the Departament de Salut de la Generalitat de Catalunya (PERIS_SLT002_16_00174).
Repisalud
Publicación Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
Repisalud
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernández-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raul
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Rémi
  • Alonso, Angel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J
  • Cañada-Pallarés, Andrés
  • Fernández, José M
  • Hansson, Mats G
  • Horvath, Rita
  • Jacobsen, Julius O B
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • Lopez-Martin, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis Alberto
  • Posada De la Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A C
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo G
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort

  • Rothwell, Joseph A.
  • Sánchez Pérez, María José|||0000-0003-4817-0757
BACKGROUND & AIMS: Colorectal cancer risk can be lowered by adherence to the World Cancer Research Fund/ American Institute for Cancer Research (WCRF/AICR) guidelines. We derived metabolic signatures of adherence to these guidelines and tested their associations with colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. METHODS: Scores reflecting adherence to the WCRF/AICR recommendations (scale, 1–5) were calculated from participant data on weight maintenance, physical activity, diet, and alcohol among a discovery set of 5738 cancer-free European Prospective Investigation into Cancer and Nutrition participants with metabolomics data. Partial least-squares regression was used to derive fatty acid and endogenous metabolite signatures of the WCRF/AICR score in this group. In an independent set of 1608 colorectal cancer cases and matched controls, odds ratios (ORs) and 95% CIs were calculated for colorectal cancer risk per unit increase in WCRF/AICR score and per the corresponding change in metabolic signatures using multivariable conditional logistic regression. RESULTS: Higher WCRF/AICR scores were characterized by metabolic signatures of increased odd-chain fatty acids, serine, glycine, and specific phosphatidylcholines. Signatures were inversely associated more strongly with colorectal cancer risk (fatty acids: OR, 0.51 per unit increase; 95% CI, 0.29–0.90; endogenous metabolites: OR, 0.62 per unit change; 95% CI, 0.50–0.78) than the WCRF/AICR score (OR, 0.93 per unit change; 95% CI, 0.86–1.00) overall. Signature associations were stronger in male compared with female participants. CONCLUSIONS: Metabolite profiles reflecting adherence to WCRF/AICR guidelines and additional lifestyle or biological risk factors were associated with colorectal cancer. Measuring a specific panel of metabolites representative of a healthy or unhealthy lifestyle may identify strata of the population at higher risk of colorectal cancer., World Cancer Research Fund International (WCRF) 20131002, European Commission grant EU-FP7/BBMRI-LPC 313010, International Agency for Research on Cancer, Danish Cancer Society, Ligue Contre le Cancer (France), General Electric, Institut Gustave-Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe German Cancer Research Center (Germany) Federal Ministry of Education & Research (BMBF) Deutsche Krebshilfe, Hellenic Health Foundation (Greece), Fondazione AIRC per la ricerca sul cancro, Consiglio Nazionale delle Ricerche (CNR), Dutch Ministry of Public Health, Welfare and Sports (The Netherlands) Netherlands Cancer Registry (The Netherlands) Netherlands Government, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Instituto de Salud Carlos III PI13/00061 PI13/01162, Junta de Andalucia, Basque Government, Regional Government of Murcia, Regional Government of Navarra, Instituto de Salud Carlos III Cooperative Research in Health (Spain) RD06/0020, Swedish Cancer Society Swedish Research Council, County Council of Skane (Sweden) County Council of Vasterbotten (Sweden), Cancer Research UK 14136 C570/A16491 C8221/A19170, UK Research & Innovation (UKRI), Medical Research Council UK (MRC) 1000143 MR/M012190/1
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raúl
  • Bayés, Mónica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean Remí
  • Alonso Sánchez, Ángel Miguel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J.
  • Cañada-Pallarés, Andrés
  • Fernández, José M.
  • Hansson, Mats G.
  • Horvath, Rita
  • Jacobsen, Julius O. B.
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • López-Martín, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis A.
  • Posada-de-la-Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N.
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A. C.
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltrán, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum

  • Urreizti, Roser
  • López-Martin, Estrella
  • Martínez-Monseny, Antonio
  • Pujadas, Montse
  • Castilla-Vallmanya, Laura
  • Pérez-Jurado, Luis Alberto
  • Serrano, Mercedes
  • Natera de Benito, Daniel
  • Martínez-Delgado, Beatriz
  • Posada-de-la-Paz, Manuel
  • Alonso, Javier
  • Marin-Reina, Purificación
  • O'Callaghan, Mar
  • Grinberg Vaisman, Daniel Raúl
  • Bermejo-Sánchez, Eva
  • Balcells Comas, Susana
Background:Pathogenic variants of the lysine acetyltransferase 6A orKAT6Agene are associated with a newlyidentified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity andspeech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initiallyreported as causing this disorder, missense mutations, to date always involving serine residues, have recently beenassociated with a form of the disorder without cardiac involvement.Results:In this study we present five new patients, four with truncating mutations and one with a missensechange and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], alsopredicted to affect splicing by in silico tools, was functionally tested in the patient's lymphocyte RNA revealing asplicing effect for this allele that would lead to a frameshift and premature truncation.Conclusions:An extensive revision of the clinical features of these five patients revealed high concordance withthe 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, ahigh bulbous nose, and recurrent infections. Other features present in some of these five patients, such ascryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

A New Pipeline for the Normalization and Pooling of Metabolomics Data

  • Viallon, Vivian
  • His, Mathilde
  • Rinaldi, Sabina
  • Breeur, Marie
  • Gicquiau, Audrey
  • Hemon, Bertrand
  • Overvad, Kim
  • Tjønneland, Anne
  • Rostgaard-Hansen, Agnetha Linn
  • Rothwell, Joseph A.
  • Lecuyer, Lucie
  • Severi, Gianluca
  • Kaaks, Rudolf
  • Johnson, Theron
  • Schulze, Matthias B.
  • Palli, Domenico
  • Agnoli, Claudia
  • Panico, Salvatore
  • Tumino, Rosario
  • Ricceri, Fulvio
  • Verschuren, W. M. Monique
  • Engelfriet, Peter
  • Onland-Moret, N. Charlotte
  • Vermeulen, Roel
  • Nøst, Therese Haugdahl
  • Urbarova, Ilona
  • Zamora-Ros, Raul
  • Rodriguez Barranco, Miguel
  • Amiano, Pilar
  • Huerta, José María
  • Ardanaz, Eva
  • Melander, Olle
  • Ottoson, Filip
  • Vidman, Linda
  • Rentoft, Matilda
  • Schmidt, Julie A.
  • Travis, Ruth C.
  • Weiderpass, Elisabete
  • Johansson, Mattias
  • Dossus, Laure
  • Jenab, Mazda
  • Gunter, Marc J.
  • Lorenzo Bermejo, Justo
  • Scherer, Dominique
  • Salek, Reza M.
  • Keski-Rahkonen, Pekka
  • Ferrari, Pietro
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers; imputation of missing data; (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis; (iii) application of linear mixed models to remove unwanted variability, including samples' originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

  • Breeur, Marie
  • Ferrari, Pietro
  • Dossus, Laure
  • Jenab, Mazda
  • Johansson, Mattias
  • Rinaldi, Sabina
  • Travis, Ruth C.
  • His, Mathilde
  • Key, Timothy J.
  • Schmidt, Julie A.
  • Overvad, Kim
  • Tjønneland, Anne
  • Kyrø, Cecilie
  • Rothwell, Joseph A.
  • Laouali, Nasser
  • Severi, Gianluca
  • Kaaks, Rudolf
  • Katzke, Verena
  • Schulze, Matthias B.
  • Eichelmann, Fabian
  • Palli, Domenico
  • Grioni, Sara
  • Panico, Salvatore
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Bueno de Mesquita, Bas
  • Olsen, Karina Standahl
  • Sandanger, Torkjel M.
  • Nøst, Therese Haugdahl
  • Quirós, José Ramón
  • Bonet Bonet, Catalina
  • Rodríguez Barranco, Miguel
  • Chirlaque, María Dolores
  • Ardanaz, Eva
  • Sandsveden, Malte
  • Manjer, Jonas
  • Vidman, Linda
  • Rentoft, Matilda
  • Muller, David
  • Tsilidis, Konstantinos K.
  • Heath, Alicia K.
  • Keun, Hector
  • Adamski, Jerzy
  • Keski-Rahkonen, Pekka
  • Scalbert, Augustin
  • Gunter, Marc J.
  • Viallon, Vivian
Background Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations. Methods We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty. Results Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk. Conclusions These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum

  • Urreizti, Roser
  • López-Martin, Estrella
  • Martínez-Monseny, Antonio
  • Pujadas, Montse
  • Castilla-Vallmanya, Laura
  • Pérez-Jurado, Luis Alberto
  • Serrano, Mercedes
  • Natera de Benito, Daniel
  • Martínez-Delgado, Beatriz
  • Posada-de-la-Paz, Manuel
  • Alonso, Javier
  • Marin-Reina, Purificación
  • O'Callaghan, Mar
  • Grinberg Vaisman, Daniel Raúl
  • Bermejo-Sánchez, Eva
  • Balcells Comas, Susana
Background:Pathogenic variants of the lysine acetyltransferase 6A orKAT6Agene are associated with a newlyidentified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity andspeech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initiallyreported as causing this disorder, missense mutations, to date always involving serine residues, have recently beenassociated with a form of the disorder without cardiac involvement.Results:In this study we present five new patients, four with truncating mutations and one with a missensechange and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], alsopredicted to affect splicing by in silico tools, was functionally tested in the patient's lymphocyte RNA revealing asplicing effect for this allele that would lead to a frameshift and premature truncation.Conclusions:An extensive revision of the clinical features of these five patients revealed high concordance withthe 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, ahigh bulbous nose, and recurrent infections. Other features present in some of these five patients, such ascryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like features

  • Lim, Albert Z.
  • McMacken, Grace M.
  • Rastelli, Francesca
  • Oláhová, Monika
  • Baty, Karen
  • Hopton, Sila
  • Falkous, Gavin
  • Töpf, Ana
  • Lochmüller, Hanns
  • Marini-Bettolo, Chiara
  • McFarland, Robert
  • Taylor, Robert W.
Mitochondrial DNA (mtDNA)-related diseases often pose a diagnostic challenge and require rigorous clinical and laboratory investigation. Pathogenic variants in the mitochondrial tRNA gene MT-TY, which encodes the tRNATyr, are a rare cause of mitochondrial disease. Here we describe a novel m.5860delTA anticodon variant in the MT-TY gene in a patient who initially presented with features akin to a childhood onset myasthenic syndrome. Using histochemical, immunohistochemical and protein studies we demonstrate that this mutation leads to severe biochemical defects of mitochondrial translation, which is reflected in the early onset and progressive phenotype. This case highlights the clinical overlap between mtDNA-related diseases and other neuromuscular disorders, and demonstrates the potential pitfalls in analysis of next generation sequencing results, given whole exome sequencing of a blood DNA sample failed to make a genetics diagnosis. Muscle biopsy remains an important requirement in the diagnosis of mitochondrial disease and in establishing the pathogenicity of novel mtDNA variants., AL, RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z); RM and RWT also receive support from the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK) (G0800674), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council L016354), UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS Specialist Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (http://www.newcastle-mitochondria.com/). GM is supported by the Association of British Neurologists Clinical Research Training Fellowship. Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data were analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A New Pipeline for the Normalization and Pooling of Metabolomics Data

  • Viallon, Vivian
  • His, Mathilde
  • Rinaldi, Sabina
  • Breeur, Marie
  • Gicquiau, Audrey
  • Hemon, Bertrand
  • Overvad, Kim
  • Tjønneland, Anne
  • Rostgaard-Hansen, Agnetha Linn
  • Rothwell, Joseph A.
  • Lecuyer, Lucie
  • Severi, Gianluca
  • Kaaks, Rudolf
  • Johnson, Theron
  • Schulze, Matthias B.
  • Palli, Domenico
  • Agnoli, Claudia
  • Panico, Salvatore
  • Tumino, Rosario
  • Ricceri, Fulvio
  • Verschuren, W. M. Monique
  • Engelfriet, Peter
  • Onland-Moret, N. Charlotte
  • Vermeulen, Roel
  • Nøst, Therese Haugdahl
  • Urbarova, Ilona
  • Zamora-Ros, Raul
  • Rodriguez Barranco, Miguel
  • Amiano, Pilar
  • Huerta, José María
  • Ardanaz, Eva
  • Melander, Olle
  • Ottoson, Filip
  • Vidman, Linda
  • Rentoft, Matilda
  • Schmidt, Julie A.
  • Travis, Ruth C.
  • Weiderpass, Elisabete
  • Johansson, Mattias
  • Dossus, Laure
  • Jenab, Mazda
  • Gunter, Marc J.
  • Lorenzo Bermejo, Justo
  • Scherer, Dominique
  • Salek, Reza M.
  • Keski-Rahkonen, Pekka
  • Ferrari, Pietro
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers; imputation of missing data; (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis; (iii) application of linear mixed models to remove unwanted variability, including samples' originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

  • Breeur, Marie
  • Ferrari, Pietro
  • Dossus, Laure
  • Jenab, Mazda
  • Johansson, Mattias
  • Rinaldi, Sabina
  • Travis, Ruth C.
  • His, Mathilde
  • Key, Timothy J.
  • Schmidt, Julie A.
  • Overvad, Kim
  • Tjønneland, Anne
  • Kyrø, Cecilie
  • Rothwell, Joseph A.
  • Laouali, Nasser
  • Severi, Gianluca
  • Kaaks, Rudolf
  • Katzke, Verena
  • Schulze, Matthias B.
  • Eichelmann, Fabian
  • Palli, Domenico
  • Grioni, Sara
  • Panico, Salvatore
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Bueno de Mesquita, Bas
  • Olsen, Karina Standahl
  • Sandanger, Torkjel M.
  • Nøst, Therese Haugdahl
  • Quirós, José Ramón
  • Bonet Bonet, Catalina
  • Rodríguez Barranco, Miguel
  • Chirlaque, María Dolores
  • Ardanaz, Eva
  • Sandsveden, Malte
  • Manjer, Jonas
  • Vidman, Linda
  • Rentoft, Matilda
  • Muller, David
  • Tsilidis, Konstantinos K.
  • Heath, Alicia K.
  • Keun, Hector
  • Adamski, Jerzy
  • Keski-Rahkonen, Pekka
  • Scalbert, Augustin
  • Gunter, Marc J.
  • Viallon, Vivian
Background Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations. Methods We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty. Results Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk. Conclusions These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

  • Barrios Barrera, Clara
  • Otero, Sol
  • Rodríguez García, Eva
  • Pedro-Botet, Juan
  • Pascual Santos, Julio
  • Menni, Cristina
Using targeted NMR spectroscopy of 227 fasting serum metabolic traits, we searched for novel metabolic signatures of renal function in 926 type 2 diabetics (T2D) and 4838 non-diabetic individuals from four independent cohorts. We furthermore investigated longitudinal changes of metabolic measures and renal function and associations with other T2D microvascular complications. 142 traits correlated with glomerular filtration rate (eGFR) after adjusting for confounders and multiple testing: 59 in diabetics, 109 in non-diabetics with 26 overlapping. The amino acids glycine and phenylalanine and the energy metabolites citrate and glycerol were negatively associated with eGFR in all the cohorts, while alanine, valine and pyruvate depicted opposite association in diabetics (positive) and non-diabetics (negative). Moreover, in all cohorts, the triglyceride content of different lipoprotein subclasses showed a negative association with eGFR, while cholesterol, cholesterol esters (CE), and phospholipids in HDL were associated with better renal function. In contrast, phospholipids and CEs in LDL showed positive associations with eGFR only in T2D, while phospholipid content in HDL was positively associated with eGFR both cross-sectionally and longitudinally only in non-diabetics. In conclusion, we provide a wide list of kidney function-associated metabolic traits and identified novel metabolic differences between diabetic and non-diabetic kidney disease., TwinsUK was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007–2013). The study also receives support from the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. TS is holder of an ERC Advanced Principal Investigator award. CB and the Genodiab-Mar cohort is supported by a grant from the Institute Carlos III (FIS-FEDER PI16/00620) and RedinRen RD16/0013/0009. CM is funded by the MRC AimHy (MR/M016560/1) project grant. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research has been supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The research leading to these results has received funding from the European Union Seventh Framework Programme under grant agreement [n°313010] (Large-scale prospective cohort studies - BBMRI-LPC; www.bbmri-lpc.org), [n°305280] (Methods for Integrated analysis of multiple Omics datasets – MIMOmics; http://www.mimomics.eu/) and under grant agreements [n°603288] (Systems Biology to Identify Molecular Targets for Vascular Disease Treatment – SysVasc; http://www.sysvasc.eu/). The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation of Finnish Diabetes Association. MAK was supported by the Sigrid Juselius Foundation, Finland. MAK works in a Unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_12013/1). PW is funded by the Academy of Finland (312476 & 312477), and the Novo Nordisk Foundation Competing Interests.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum

  • Urreizti, Roser
  • López Martín, Estrella
  • Martínez Monseny, Antonio Federico
  • Pujadas, Montserrat
  • Castilla-Vallmanya, Laura
  • Pérez Jurado, Luis Alberto
  • Serrano, Mercedes
  • Natera de Benito, Daniel
  • Martínez Delgado, Beatriz
  • Posada de la Paz, Manuel
  • Alonso, Javier
  • Marín Reina, Purificación
  • O'Callaghan, Mar
  • Grinberg, Daniel
  • Bermejo Sánchez, Eva
  • Balcells, Susana
Background: Pathogenic variants of the lysine acetyltransferase 6A or KAT6A gene are associated with a newly identified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity and speech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initially reported as causing this disorder, missense mutations, to date always involving serine residues, have recently been associated with a form of the disorder without cardiac involvement. Results: In this study we present five new patients, four with truncating mutations and one with a missense change and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], also predicted to affect splicing by in silico tools, was functionally tested in the patient’s lymphocyte RNA revealing a splicing effect for this allele that would lead to a frameshift and premature truncation. Conclusions: An extensive revision of the clinical features of these five patients revealed high concordance with the 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, a high bulbous nose, and recurrent infections. Other features present in some of these five patients, such as cryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome., Funding was from Associació Síndrome Opitz C, Terrassa, Spain; Spanish Ministerio de Economía y Competitividad (SAF2016–75948-R) and from CIBERER (U720). SpainUDP is an initiative funded by the Instituto de Salud Carlos III. Also, the whole exome sequencing of patient 3 was funded through 2016 BBMRI-LPC Call (FP7/2007–2013, grant agreement n° 313010) and patient 5 was sequenced thanks to the PERIS·URDCat program, funded by the Departament de Salut de la Generalitat de Catalunya (PERIS_SLT002_16_00174).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)